(Q35681641)

English

Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: Post hoc analysis of the ASSET-K study

scientific article published on 3 July 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 August 2017

Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: Post hoc analysis of the ASSET-K study (English)

1 reference

Europe PubMed Central

9 August 2017

type 2 diabetes

1 reference

based on heuristic

inferred from title

author name string

Shinichi Umezawa

1

1 reference

Europe PubMed Central

9 August 2017

Akira Kubota

2

1 reference

Europe PubMed Central

9 August 2017

Hajime Maeda

3

1 reference

Europe PubMed Central

9 August 2017

Akira Kanamori

4

1 reference

Europe PubMed Central

9 August 2017

Kiyokazu Matoba

5

1 reference

Europe PubMed Central

9 August 2017

Yasuyuki Jin

6

1 reference

Europe PubMed Central

9 August 2017

Fuyuki Minagawa

7

1 reference

Europe PubMed Central

9 August 2017

Mitsuo Obana

8

1 reference

Europe PubMed Central

9 August 2017

Kotaro Iemitsu

9

1 reference

Europe PubMed Central

9 August 2017

Shogo Ito

10

1 reference

Europe PubMed Central

9 August 2017

Hikaru Amamiya

11

1 reference

Europe PubMed Central

9 August 2017

Mizuki Kaneshiro

12

1 reference

Europe PubMed Central

9 August 2017

Masahiko Takai

13

1 reference

Europe PubMed Central

9 August 2017

Hideaki Kaneshige

14

1 reference

Europe PubMed Central

9 August 2017

Kazuhiko Hoshino

15

1 reference

Europe PubMed Central

9 August 2017

Masashi Ishikawa

16

1 reference

Europe PubMed Central

9 August 2017

Nobuaki Minami

17

1 reference

Europe PubMed Central

9 August 2017

Tetsuro Takuma

18

1 reference

Europe PubMed Central

9 August 2017

Nobuo Sasai

19

1 reference

Europe PubMed Central

9 August 2017

Sachio Aoyagi

20

1 reference

Europe PubMed Central

9 August 2017

Takehiro Kawata

21

1 reference

Europe PubMed Central

9 August 2017

Atsuko Mokubo

22

1 reference

Europe PubMed Central

9 August 2017

Yukiko Miyairi

23

1 reference

Europe PubMed Central

9 August 2017

Hiroshi Takeda

24

1 reference

Europe PubMed Central

9 August 2017

Shin Honda

25

1 reference

Europe PubMed Central

9 August 2017

Hideo Machimura

26

1 reference

Europe PubMed Central

9 August 2017

Tetsuya Motomiya

27

1 reference

Europe PubMed Central

9 August 2017

Manabu Waseda

28

1 reference

Europe PubMed Central

9 August 2017

Yoshikazu Naka

29

1 reference

Europe PubMed Central

9 August 2017

Yasushi Tanaka

30

1 reference

Europe PubMed Central

9 August 2017

Yasuo Terauchi

31

1 reference

Europe PubMed Central

9 August 2017

Ikuro Matsuba

32

1 reference

Europe PubMed Central

9 August 2017

publication date

3 July 2015

1 reference

Europe PubMed Central

9 August 2017

BMC Endocrine Disorders

1 reference

Europe PubMed Central

9 August 2017

15

1 reference

Europe PubMed Central

9 August 2017

34

1 reference

Europe PubMed Central

9 August 2017

copyright license

Creative Commons Attribution 4.0 International

3 July 2015

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

https://scigraph.springernature.com/pub.10.1186/s12902-015-0033-2

0 references

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4490678

12 July 2018

The durability of sitagliptin in elderly patients with type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4490678

12 July 2018

Dipeptidyl peptidase-4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4490678

12 July 2018

Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4490678

12 July 2018

Use of the Japanese health insurance claims database to assess the risk of acute pancreatitis in patients with diabetes: comparison of DPP-4 inhibitors with other oral antidiabetic drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4490678

12 July 2018

Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4490678

12 July 2018

Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4490678

12 July 2018

Factors associated with reduced efficacy of sitagliptin therapy: analysis of 93 patients with type 2 diabetes treated for 1.5 years or longer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4490678

12 July 2018

Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4490678

12 July 2018

Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4490678

12 July 2018

Pleiotropic effects of sitagliptin in the treatment of type 2 diabetes mellitus patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4490678

12 July 2018

Management of type 2 diabetes mellitus in the elderly

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4490678

12 July 2018

Management of diabetes mellitus in the elderly

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4490678

12 July 2018

Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4490678

12 July 2018

Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4490678

12 July 2018

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4490678

12 July 2018

Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4490678

12 July 2018

Hypoglycaemia in elderly patients with diabetes mellitus: causes and strategies for prevention

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4490678

12 July 2018

Mortality in older people with diabetes mellitus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4490678

12 July 2018

Impact of treatment with saxagliptin on glycaemic stability and β-cell function in the SAVOR-TIMI 53 study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4490678

25 September 2018

Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4490678

25 September 2018

Safety of sitagliptin in elderly patients with type 2 diabetes: a pooled analysis of 25 clinical studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4490678

25 September 2018

Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4490678

25 September 2018

Long-term efficacy and safety of sitagliptin in the treatment of Japanese Type 2 diabetes (ASSET-K1) to a target of HbA1c <7%.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4490678

25 September 2018

Glucose tolerance status and risk of dementia in the community: the Hisayama study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4490678

25 September 2018

Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4490678

25 September 2018

Utility of casual postprandial glucose levels in type 2 diabetes management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4490678

25 September 2018

Effects of sitagliptin on the serum creatinine in Japanese type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/26137940

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/26137940

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effective surgical treatment of obesity may be mediated by ablation of the lipogenic gut hormone gastric inhibitory polypeptide (GIP): evidence and clinical opportunity for development of new obesity-diabetes drugs?

1 reference

https://pubmed.ncbi.nlm.nih.gov/26137940

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Diabetes in the elderly

1 reference

https://pubmed.ncbi.nlm.nih.gov/26137940

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/S12902-015-0033-2

1 reference

Europe PubMed Central

9 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

9 August 2017

1 reference

Europe PubMed Central

9 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35681641&oldid=1856133116"